Ignite Creation Date:
2024-05-05 @ 6:47 PM
Last Modification Date:
2024-10-26 @ 9:37 AM
Study NCT ID:
NCT00542412
Status:
COMPLETED
Last Update Posted:
2007-10-11
First Post:
2007-10-10
Brief Title:
CARE Canadian ALS Riluzole Evaluation
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Care Canadian ALS Riluzole Evaluation Multicentre Phase IV Comparative Study of the Effects of Riluzole 50mg Bid on the Survival of ALS Subjects Compared to Historical Controls
Status:
COMPLETED
Status Verified Date:
2007-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate the efficacy of riluzole 50-mg bid defined by comparing the percentage of riluzole-treated subjects who experienced death permanently assisted ventilation PAV or tracheostomy to a group of recent historical controls for the treatment of amyotrophic lateral sclerosis ALS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None